- 501 Orchard Road, #04-08 Wheelock Place, Singapore 238880
- (65) 6235 4429
- hello@vidaskinclinic.com
- (65) 9830 0597
Ultherapy isn’t designed or indicated to reduce facial fat; it’s built to stimulate collagen at the SMAS and dermal layers. That said, unintended facial volume loss has been reported, more often described anecdotally by patients and clinicians than confirmed in large controlled studies, and it’s recognised in the medical literature as a rare but real complication, usually linked to how a treatment was planned and delivered rather than the technology itself. “It’s something I take seriously and plan around for every patient, not something I’d dismiss as internet rumour,” says Dr Kay Low, senior aesthetic physician at VIDASKIN.
Worth knowing upfront: a good part of what people interpret as fat loss after Ultherapy usually isn’t. It’s often ordinary post-treatment swelling settling down, the treatment’s genuine lifting effect making the face read as more contoured, or age-related volume loss that would have continued regardless of treatment. The section below, “Fat Loss Or Something Else?”, walks through how to tell these apart before this guide gets into the deeper mechanism and evidence.
Ultherapy works by delivering focused ultrasound energy that heats tissue to around 60 to 70°C at specific depths, close to where facial fat compartments sit. It’s a reasonable question to ask whether that heat could affect fat as well as collagen, and the honest answer is that it can, under certain conditions, even though that’s not what the treatment is designed to do.
Patient and clinician reports of post-Ultherapy volume loss typically describe hollowing in specific areas, the temples, under the eyes, or the mid-cheek, appearing gradually over four to eight weeks after treatment, rather than an immediate change. Dr Kay Low notes that these reports cluster around the same higher-risk areas and patient profiles repeatedly, which is useful information even without large trial data behind it.
Some of what patients interpret as fat loss in the days after treatment is actually swelling settling down. Mild post-treatment swelling can temporarily change how full or contoured an area looks, and this typically resolves within the first one to two weeks, well before any genuine collagen or fat-related change would be expected to show.
Because Ultherapy’s SMAS-level effect genuinely lifts and tightens supporting tissue, a face can look more contoured or “sharper” afterward in a way that’s easy to mistake for volume loss, when it’s actually the intended lifting effect doing its job.
Facial fat volume naturally declines with age independent of any treatment, so some patients notice ongoing volume changes in the months after Ultherapy that would have happened anyway. Distinguishing this from a treatment-related effect usually requires looking at the specific area affected, the timeline, and whether it matches a pattern of gradual, generalised ageing or a more localised change in a high-risk zone.
Ultherapy’s intended target is the SMAS and dermis, not the subcutaneous fat compartments that sit around and beneath them. But the face isn’t a set of cleanly separated layers; fat pads sit close to the SMAS in several areas, particularly the temple, buccal, and periorbital regions, which is where unintended thermal effects on fat are more plausible.
Ultherapy PRIME treats at three fixed depths, 4.5mm, 3.0 mm, and 1.5mm, rather than a continuous range, which is part of what makes outcomes predictable when used correctly. Overlapping passes, excessive energy, or repeated sessions too close together are what tend to push thermal effects beyond the intended zone and into adjacent fat, according to published complication reviews.
This is where real-time visualisation, the “see” in Ultherapy PRIME’s See-Plan-Treat protocol, matters directly for this particular risk. Being able to see fat pad thickness and tissue structure before treating allows Dr Kay Low to calibrate depth and energy for that specific area, rather than applying the same settings regardless of how much fat sits underneath.
A recent review of HIFU complications across 22 studies identified cheek fat atrophy as a recognised, if uncommon, complication, generally linked to tissue overheating from improper device settings, overlapping passes on the same area, or inadequate time between energy-based treatments. The same review found that operators without adequate aesthetic medicine training were significantly more likely to cause complications of this kind.
There’s no large-scale, systematic data on exactly how often unintended fat loss occurs, which patients are affected, or precisely how much energy or how many overlapping passes tips risk upward. Much of what’s understood comes from case reports and clinical experience rather than randomised trials, which is a genuine gap in the evidence rather than something to paper over.
Patients who are naturally lean-faced or have a more angular facial structure with less baseline fat have less of a buffer if thermal effects do extend slightly beyond the intended zone, and Dr Kay Low treats this group more conservatively as a result.
Patients over roughly 35 who already show some midface deflation, or who’ve previously had fat-reducing procedures such as buccal fat removal or fat-freezing treatments, are also considered higher-risk for this specific complication, since there’s simply less fat present to begin with.
Dr Kay Low’s approach at VIDASKIN starts with mapping fat pad thickness and skeletal support in the areas being considered for treatment, before any energy is delivered, and calibrating depth and energy specifically for that patient rather than using a single default setting for everyone.
Higher-risk zones, the temples, under-eye area, mid-cheek and buccal region, are treated more conservatively or, depending on the individual assessment, avoided altogether, with treatment focused on areas like the lower face, jawline and neck where the risk-benefit balance is more favourable.
If you notice hollowing or volume loss in the weeks after Ultherapy, particularly in the temples, under the eyes or mid-cheek, the first step is to go back to the treating clinic for an assessment rather than assuming the worst immediately, since early swelling and genuine volume change can look similar at first. Dr Kay Low reviews patients who raise this concern, distinguishes what’s actually happening, and, where volume has genuinely been affected, can discuss options such as dermal filler to restore it.
At VIDASKIN, Dr Kay Low is an experienced aesthetic physician trained in the See-Plan-Treat protocol, and performs treatment herself rather than delegating it. Her starting point with every patient is working out what’s actually causing the change they’re seeing before recommending Ultherapy at all.
If your main concern is a softening jawline or early jowling, the most useful first step is a consultation with Dr Kay Low to confirm whether Ultherapy PRIME is actually the right fit for what’s going on.
To learn more or book a consultation with Dr Kay Low, visit or contact us here today
Dr. Kay Low is a UK-trained medical doctor with over 7 years of clinical experience across the UK and Singapore, specialising in aesthetic medicine. A graduate of the University of Cambridge, she has worked across multiple medical and surgical disciplines in the UK and Singapore before completing postgraduate training in Family Medicine and advanced training in aesthetic medicine.
